HAUMANN BRETT K 4
4 · Theravance Biopharma, Inc. · Filed Aug 24, 2020
Insider Transaction Report
Form 4
HAUMANN BRETT K
SVP, Clinical Development
Transactions
- Sale
Ordinary Shares
2020-08-21$18.29/sh−25,000$457,240→ 282,810 total - Tax Payment
Ordinary Shares
2020-08-20$18.22/sh−4,646$84,650→ 307,810 total
Footnotes (1)
- [F1]This transaction was executed in multiple trades at prices from $18.22 to $18.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.